JP2017510572A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510572A5 JP2017510572A5 JP2016556962A JP2016556962A JP2017510572A5 JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5 JP 2016556962 A JP2016556962 A JP 2016556962A JP 2016556962 A JP2016556962 A JP 2016556962A JP 2017510572 A5 JP2017510572 A5 JP 2017510572A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- aliphatic
- present
- alkyl
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *C(C1C*c2cc(*)c(C=CC(C=*)=CC=C*)c(*)c2)ON=C1c1c(*)cccc1* Chemical compound *C(C1C*c2cc(*)c(C=CC(C=*)=CC=C*)c(*)c2)ON=C1c1c(*)cccc1* 0.000 description 4
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461952754P | 2014-03-13 | 2014-03-13 | |
| US61/952,754 | 2014-03-13 | ||
| US201462061463P | 2014-10-08 | 2014-10-08 | |
| US62/061,463 | 2014-10-08 | ||
| PCT/US2015/020582 WO2015138986A1 (en) | 2014-03-13 | 2015-03-13 | Fxr agonists and methods for making and using |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017510572A JP2017510572A (ja) | 2017-04-13 |
| JP2017510572A5 true JP2017510572A5 (enExample) | 2017-06-29 |
Family
ID=54072502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016556962A Pending JP2017510572A (ja) | 2014-03-13 | 2015-03-13 | Ｆｘｒアゴニストならびに作製および使用のための方法 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP3116878A4 (enExample) |
| JP (1) | JP2017510572A (enExample) |
| KR (1) | KR20160132111A (enExample) |
| AU (1) | AU2015229072A1 (enExample) |
| CA (1) | CA2942403A1 (enExample) |
| WO (1) | WO2015138986A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| US10301268B2 (en) | 2014-03-13 | 2019-05-28 | The Salk Institute For Biological Studies | Analogs of fexaramine and methods of making and using |
| US10077268B2 (en) | 2014-03-13 | 2018-09-18 | Salk Institute For Biological Studies | FXR agonists and methods for making and using |
| WO2016014927A2 (en) | 2014-07-24 | 2016-01-28 | W.R. Grace & Co.-Conn. | Crystalline form of nicotinamide riboside |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| KR102629310B1 (ko) | 2015-03-09 | 2024-01-24 | 더블유.알. 그레이스 앤드 캄파니-콘. | 니코틴아미드 리보사이드의 결정 형태 |
| KR20180052678A (ko) | 2015-09-16 | 2018-05-18 | 메타크린, 인크. | 파네소이드 x 수용체 아고니스트 및 이의 용도 |
| WO2017078928A1 (en) * | 2015-11-06 | 2017-05-11 | Salk Institute For Biological Studies | Fxr agonists and methods for making and using |
| WO2017143134A1 (en) * | 2016-02-19 | 2017-08-24 | Alios Biopharma, Inc. | Fxr modulators and methods of their use |
| BR112018075734A2 (pt) * | 2016-06-13 | 2019-04-02 | Gilead Sciences, Inc. | composto, composição farmacêutica, método para tratar um paciente com uma doença ou condição mediada pelo menos em parte por fxr, e, uso de um composto. |
| CA3252823A1 (en) * | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| KR102218498B1 (ko) * | 2016-09-14 | 2021-02-22 | 노파르티스 아게 | Fxr 작용제들의 조합물 |
| AU2018223146B2 (en) | 2017-02-21 | 2023-12-21 | Genfit | Combination of a PPAR agonist with a FXR agonist |
| CN110461328A (zh) | 2017-03-28 | 2019-11-15 | 吉利德科学公司 | 治疗肝疾病的治疗组合 |
| HRP20251321T1 (hr) | 2018-09-18 | 2025-12-05 | Eli Lilly And Company | Agonisti farnezoid x receptora i njihova primjena |
| EP4360632B1 (en) | 2019-01-15 | 2025-10-29 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
| US11524005B2 (en) | 2019-02-19 | 2022-12-13 | Gilead Sciences, Inc. | Solid forms of FXR agonists |
| AU2020312735A1 (en) | 2019-07-18 | 2021-12-16 | Enyo Pharma | Method for decreasing adverse-effects of interferon |
| CN114080234A (zh) | 2019-07-23 | 2022-02-22 | 诺华股份有限公司 | 包含fxr激动剂的治疗 |
| EP4003349A1 (en) | 2019-07-23 | 2022-06-01 | Novartis AG | Combination treatment of liver diseases using fxr agonists |
| CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
| WO2021053618A1 (en) | 2019-09-19 | 2021-03-25 | Novartis Ag | Treatment comprising fxr agonists |
| EP4041233A1 (en) | 2019-09-30 | 2022-08-17 | Novartis AG | Treatment comprising the use of fxr agonists |
| TW202135811A (zh) | 2019-12-20 | 2021-10-01 | 瑞士商諾華公司 | 使用整聯蛋白抑制劑組合治療肝臟疾病 |
| US20230060715A1 (en) | 2020-01-15 | 2023-03-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of fxr agonists for treating an infection by hepatitis d virus |
| BR112022018553A2 (pt) | 2020-03-18 | 2022-11-29 | Metacrine Inc | Formulações de um agonista do receptor x farnesoide |
| MX2022011582A (es) | 2020-03-18 | 2022-12-13 | Metacrine Inc | Formas cristalinas de un agonista del receptor farnesoide x. |
| WO2022101853A1 (en) | 2020-11-16 | 2022-05-19 | Novartis Ag | Method of determining liver fibrosis |
| US20240100125A1 (en) | 2021-01-14 | 2024-03-28 | Enyo Pharma | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection |
| CN117320722A (zh) | 2021-04-28 | 2023-12-29 | 埃尼奥制药公司 | 使用fxr激动剂作为联合治疗强烈增强tlr3激动剂的作用 |
| CN120698876A (zh) * | 2025-06-03 | 2025-09-26 | 上海埃思凯特科技有限公司 | 一种吉非罗齐氘代衍生物及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI329111B (en) * | 2002-05-24 | 2010-08-21 | X Ceptor Therapeutics Inc | Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| CA2633243C (en) * | 2005-12-15 | 2014-05-27 | Exelixis, Inc. | Azepinoindole derivatives as pharmaceutical agents |
| US20080300235A1 (en) * | 2007-06-01 | 2008-12-04 | Wyeth | FXR Agonists for Reducing LOX-1 Expression |
| US20090163474A1 (en) * | 2007-10-19 | 2009-06-25 | Wyeth | FXR Agonists for the Treatment of Nonalcoholic Fatty Liver and Cholesterol Gallstone Diseases |
| US20090215748A1 (en) * | 2007-12-20 | 2009-08-27 | Wyeth | FXR agonists for treating vitamin D associated diseases |
| WO2010036362A1 (en) * | 2008-09-26 | 2010-04-01 | Wyeth | 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors |
| EP3593802A3 (en) * | 2010-05-26 | 2020-03-25 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| CA2842707A1 (en) * | 2011-08-04 | 2013-02-07 | Lumena Pharmaceuticals, Inc. | Bile acid recycling inhibitors for treatment of pancreatitis |
-
2015
- 2015-03-13 CA CA2942403A patent/CA2942403A1/en not_active Abandoned
- 2015-03-13 EP EP15761517.0A patent/EP3116878A4/en not_active Withdrawn
- 2015-03-13 AU AU2015229072A patent/AU2015229072A1/en not_active Abandoned
- 2015-03-13 WO PCT/US2015/020582 patent/WO2015138986A1/en not_active Ceased
- 2015-03-13 KR KR1020167028569A patent/KR20160132111A/ko not_active Withdrawn
- 2015-03-13 JP JP2016556962A patent/JP2017510572A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2015138986A1 (en) | Fxr agonists and methods for making and using | |
| JP7665619B2 (ja) | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 | |
| TWI358296B (en) | Acid secretion inhibitor | |
| CN113056271B (zh) | 法尼醇x受体激动剂及其用途 | |
| JP6632532B2 (ja) | オートタキシン阻害活性を有するピリミジノン誘導体 | |
| CN113056264A (zh) | 法尼醇x受体激动剂及其用途 | |
| WO2017078928A1 (en) | Fxr agonists and methods for making and using | |
| TW200900064A (en) | Pyrrole compounds | |
| AU2015229055A1 (en) | Analogs of fexaramine and methods of making and using | |
| JP6276760B2 (ja) | ４−アルキニルイミダゾール誘導体およびそれを有効成分として含有する医薬 | |
| WO2020061118A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| KR102433588B1 (ko) | 할로겐 치환 헤테로환 화합물의 염 | |
| EP2296659A2 (en) | Drug combinations comprising a dgat inhibitor and a ppar-agonist | |
| CN113056265A (zh) | 法尼醇x受体激动剂及其用途 | |
| CN112955448A (zh) | 芳环或芳杂环类化合物及其制备方法和医药用途 | |
| AU2017293271A1 (en) | Imidazo[1,2-α]pyridine derivatives, methods for preparing the same and use thereof | |
| IL189666A (en) | Pyridinaminosulfonyl substituted benzamides as inhibitors of cytochrome p450 3a4 (cyp3a4) | |
| TW200920366A (en) | 5-membered heterocyclic compound | |
| CN104203236A (zh) | 杂环酰胺衍生物和含有其的药物 | |
| TWI893238B (zh) | 二氯酚hsd17b13抑制劑及其用途 | |
| WO2010007943A1 (ja) | 含窒素複素環化合物 | |
| TW202304898A (zh) | 噻唑/異噻唑hsd17b13抑制劑及其用途 | |
| TW202337449A (zh) | 2-取代噻唑hsd17b13抑制劑及其用途 | |
| CA2470427A1 (en) | Compositions and methods for treating heart failure | |
| JP2005514432A5 (enExample) |